

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-J-036**

Please note we have provided this information for the period July to September 2022.

You asked:

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Abemaciclib patients – total of 8 patients on all combinations
Abemaciclib + Fulvestrant	
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	<5*
Capecitabine as a single agent	10
Eribulin as a single agent or in combination	8
Everolimus + Exemestane	<5* patients on Everolimus via ChemoCare – Exemestane not prescribed on our system
Fulvestrant as a single agent	17 as a single agent and combined with aromatase inhibitors
Lapatinib	0
Neratinib	0
PARP inhibitors (Olaparib/Talazoparib)	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Palbociclib patients – total of 33 patients on all combinations
Palbociclib + Fulvestrant	
Pembrolizumab	0
Platinum (e.g. carboplatin or cisplatin) as a single agent	9
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	We are unable to split Ribociclib patients – total of 5 patients on all combinations
Ribociclib + Fulvestrant	



Sacituzumab Govitecan	0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	49
Taxane and/or Anthracycline in combination	41
Trastuzumab as a single agent or in combination	25
Trastuzumab emtansine	10
Trastuzumab deruxtecan	<5*
Any other active systemic anti-cancer therapy	<5*

2. Does your Health Board participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.

In the time period specified, the Health Board has taken part in the below trials;

- Destiny 09
- Nostra
- Optima
- Palmira
- Partner
- SMR 3760

A total of 21 patients are participating across all 6 active trials.

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

